• Home
  • About
    • Overview
    • Sharing Data
    • ORCID
  • Help
  • History (241)
    • Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation.
    • Atypical dimensions of caregiver-adolescent interaction in an economically disadvantaged sample.
    • A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study.
    • Nrf2-modulation by seleno-hormetic agents and its potential for radiation protection.
    • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
    • See All 241 Pages
  • search
    • Find People
    • Find Everything
Login to edit your profile (add a photo, awards, links to other websites, etc.)
  • Edit My Profile
  • My Person List (0)

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.

Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. Thromb Haemost. 2004 Dec; 92(6):1182-93.

View in: PubMed

subject areas
  • Animals
  • Anticoagulants
  • Area Under Curve
  • Blood Coagulation
  • Cardiovascular Diseases
  • Clinical Trials as Topic
  • Coronary Artery Disease
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Factor Xa
  • Factor Xa Inhibitors
  • Humans
  • International Normalized Ratio
  • Mice
  • Models, Biological
  • Models, Chemical
  • Naphthalenes
  • Pilot Projects
  • Platelet Aggregation Inhibitors
  • Propionates
  • Rats
  • Thrombin
  • Thromboplastin
  • Thrombosis
  • Time Factors

authors with profiles
  • Robert Harrington